Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Return on Sales (2016 - 2025)

Guided Therapeutics' Return on Sales history spans 16 years, with the latest figure at 0.02% for Q4 2025.

  • On a quarterly basis, Return on Sales rose 650.0% to 0.02% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.04%, a 341.0% increase, with the full-year FY2025 number at 0.04%, up 341.0% from a year prior.
  • Return on Sales hit 0.02% in Q4 2025 for Guided Therapeutics, up from 0.12% in the prior quarter.
  • Over the last five years, Return on Sales for GTHP hit a ceiling of 0.04% in Q3 2021 and a floor of 24.42% in Q1 2025.
  • Historically, Return on Sales has averaged 2.5% across 5 years, with a median of 0.57% in 2024.
  • The widest YoY moves for Return on Sales: up 650bps in 2025, down -2375bps in 2025.
  • Tracing GTHP's Return on Sales over 5 years: stood at 0.07% in 2021, then tumbled by -4414bps to 3.34% in 2022, then soared by 96bps to 0.12% in 2023, then plummeted by -5305bps to 6.52% in 2024, then surged by 100bps to 0.02% in 2025.
  • Business Quant data shows Return on Sales for GTHP at 0.02% in Q4 2025, 0.12% in Q3 2025, and 0.07% in Q2 2025.